GS 7977 (sovaldi) followed the same route -- P1 trials in NZ then trials in the US. So did Idix 21437. Idix got a buyout after it's P1 trial in NZ. So will Achn for 3422!! I expect 3422 will equal sovaldi in efficacy and safety. I expect the Achn buyout will happen at $4-11 billion.